Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes-Reference-Cited by-同舟云学术

Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes

Published:2017-08-14 Issue:11 Volume:26 Page:1357-1366
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Gawade Prasad L.¹^ORCID,Berlin Jesse A.²,Henry David H.³,Tomita Dianne⁴,Brooks Barry D.⁵,Franklin Janet⁶,Bradbury Brian D.¹,Critchlow Cathy W.¹

Affiliation:

1. Center for Observational Research; Amgen Inc.; Thousand Oaks CA USA

2. Epidemiology; Johnson & Johnson; New Brunswick NJ USA

3. Department of Medicine; University of Pennsylvania; Philadelphia PA USA

4. Global Biostatistical Science; Amgen Inc.; Thousand Oaks CA USA

5. The US Oncology Network; Dallas TX USA

6. Global Development; Amgen Inc.; Thousand Oaks CA USA

Funder

Amgen

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference30 articles.

1. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients;Bohlius;J Natl Cancer Inst,2006

2. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia;Bennett;JAMA,2008

3. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis;Bohlius;J Natl Cancer Inst,2005

4. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia-reply;Bennett;JAMA,2008

5. Correction of anemia with epoetin alfa in chronic kidney disease;Singh;N Engl J Med,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy;Drugs & Therapy Perspectives;2022-12-06

2. Radix Astragali polysaccharide RAP directly protects hematopoietic stem cells from chemotherapy-induced myelosuppression by increasing FOS expression;International Journal of Biological Macromolecules;2021-07

3. Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA 's risk evaluation and mitigation strategy lifecycle;Pharmacoepidemiology and Drug Safety;2021-02-22

4. Association Between Reimbursement Incentives and Physician Practice in Oncology;JAMA Oncology;2019-06-01

5. Erythropoietin inhibits chemotherapy-induced cell death and promotes a senescence-like state in leukemia cells;Cell Death & Disease;2019-01